BRD3308 is a highly selective HDAC3 inhibitor with an IC50 of 54 nM. BRD3308 is 23-fold selectivity for HDAC3 over HDAC1 (IC50 of 1.26 μM) or HDAC2 (IC50 of 1.34 μM). BRD3308 suppresses pancreatic β-cell apoptosis induced by inflammatory cytokines or glucolipotoxic stress, and increases functional insulin release. BRD3308 activates HIV-1 transcription and disrupts HIV-1 latency.
HDAC Inhibitors Related Prodcuts:
Mocetinostat; Dacinostat; Belinostat; Tacedinaline; RoMidepsin; Givinostat; Vorinostat; Tubastatin A HCl; Entinostat; Panobinostat; Trichostatin A; Pracinostat; AR-42; Ricolinostat; WT161; ACY-738; Tasquinimod; Domatinostat; LMK-235